Breast feeding, parity and breast cancer subtypes in a Spanish cohort by Redondo Marey, Carmen Maria et al.
Breast Feeding, Parity and Breast Cancer Subtypes in a
Spanish Cohort
Carmen M. Redondo1*., Manuela Gago-Domı´nguez2., Sara Miranda Ponte1, Manuel Enguix Castelo3,
Xuejuan Jiang4, Ana Alonso Garcı´a5, Maite Pen˜a Ferna´ndez6, Marı´a Ausencia Tome´7, Ma´ximo Fraga8,
Francisco Gude9, Marı´a Elena Martı´nez10, Vı´ctor Mun˜oz Garzo´n3, A´ngel Carracedo2, J. Esteban Castelao1
1Oncology and Genetics Unit, Genomic Medicine Group, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 2Genomic Medicine Group, Galician Foundation of
Genomic Medicine, Complejo Hospitalario Universitario de Santiago, IDIS, Santiago de Compostela, Spain, 3 Radiotherapy Department, Complejo Hospitalario
Universitario de Vigo, Vigo, Spain, 4Ophtalmology and Preventive Medicine Department, University of Southern California, Los Angeles, California, United States of
America, 5 Radiotherapy Department, Hospital Universitario Central de Asturias, Oviedo, Spain, 6Ginecology Department, Complejo Hospitalario Universitario de
Santiago, Santiago de Compostela, Spain, 7 Endocrinology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 8 Pathology
Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 9Clinical Epidemiology Unit, Complejo Hospitalario Universitario de
Santiago, Santiago de Compostela, Spain, 10University of California San Diego, Moores Cancer Center, San Diego, California, United Sates of America
Abstract
Background: Differences in the incidence and outcome of breast cancer among Hispanic women compared with white
women are well documented and are likely explained by ethnic differences in genetic composition, lifestyle, or
environmental exposures.
Methodolgy/Principal Findings: A population-based study was conducted in Galicia, Spain. A total of 510 women
diagnosed with operable invasive breast cancer between 1997 and 2010 participated in the study. Data on demographics,
breast cancer risk factors, and clinico-pathological characteristics were collected. The different breast cancer tumor subtypes
were compared on their clinico-pathological characteristics and risk factor profiles, particularly reproductive variables and
breastfeeding. Among the 501 breast cancer patients (with known ER and PR receptors), 85% were ER+/PR+ and 15% were
ER-&PR-. Among the 405 breast cancer with known ER, PR and HER2 status, 71% were ER+/PR+/HER2- (luminal A), 14% were
ER+/PR+/HER2+ (luminal B), 10% were ER2/PR2/HER2- (triple negative breast cancer, TNBC), and 5% were ER2/PR2/HER2+
(non-luminal). A lifetime breastfeeding period equal to or longer than 7 months was less frequent in case patients with
TNBC (OR = 0.25, 95% CI = 0.08–0.68) compared to luminal A breast cancers. Both a low (2 or fewer pregnancies) and a high
(3–4 pregnancies) number of pregnancies combined with a long breastfeeding period were associated with reduced odds
of TNBC compared with luminal A breast cancer, although the association seemed to be slightly more pronounced among
women with a low number of pregnancies (OR = 0.09, 95% CI = 0.005–0.54).
Conclusions/Significance: In case-case analyses with the luminal A cases as the reference group, we observed a lower
proportion of TNBC among women who breastfed 7 or more months. The combination of longer breastfeeding duration
and lower parity seemed to further reduce the odds of having a TNBC compared to a luminal A breast cancer.
Citation: Redondo CM, Gago-Domı´nguez M, Ponte SM, Castelo ME, Jiang X, et al. (2012) Breast Feeding, Parity and Breast Cancer Subtypes in a Spanish
Cohort. PLoS ONE 7(7): e40543. doi:10.1371/journal.pone.0040543
Editor: Amanda Ewart Toland, Ohio State University Medical Center, United States of America
Received December 14, 2011; Accepted June 12, 2012; Published July 11, 2012
Copyright:  2012 Redondo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Programa Grupos Emergentes EMERCIII, Instituto de Salud Carlos III, Cancer Genetics Unit Complejo Hospitalario Universitario de Vigo, Spain (IP: JEC).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: carmen.redondo.marey@sergas.es
. These authors contributed equally to this work.
Introduction
In the US, breast cancer impacts each racial group differently
[1–4]. Compared with non-Hispanic White (NHW) women,
Hispanic women have a lower incidence rate of breast cancer,
however, once diagnosed with this disease they are more likely to
die from it [5]. Studies [6,7] have found that despite equal access
to health care services, differences persist in the presentation of
Hispanic women with breast cancer compared with NHW
women, suggesting a biologic basis for the racial/ethnic differenc-
es. The potential biological differences among breast cancers may
result from racial/ethnic differences in genetic composition,
lifestyles or environmental exposures [7].
It has been reported that women diagnosed with estrogen
receptor-positive (ER+)/progesterone receptor-positive (PR+) tu-
mors are more responsive to hormonal treatment and have a
better prognosis than those diagnosed with estrogen receptor-
negative (ER-)/progesterone receptor negative (PR-) tumors,
suggesting etiologic heterogeneity of hormone-receptor defined
subtypes of breast cancer [8,9]. Consistently, disparate risk factor
profiles for breast cancer according to ER and PR status have been
reported [1,10]. In general, Hispanic patients with breast cancer
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tend to have ER- tumors more disproportionately than NHW
women although the difference was not as great as that seen
between black and NHW women [11,12].
In this study, we describe the characteristics of breast cancer
subtypes defined by ER, PR and HER2 receptor status and
assessed the associations between reproductive factors and
breastfeeding and tumor subtypes in a case series of female breast
cancer patients from Galicia, a region located in the northwest
part of Spain, whose history has been defined by mass emigration
to Latin America [13]. Because this region has been the European
state with one of the highest emigration to Latin America in the
1800s and 1900s, its population could be, at least partially, a
contributor of the European ancestry to Hispanics in the US. In
addition, the Galician population could provide a contrast group
to Hispanics from regions in the U.S. such as the San Luis Valley,
Colorado in the US, many of whom self-identify as being of
‘‘Spanish origin’’ [14].
To our knowledge, this is in one of the first studies to explore
these relationships in this population.
Materials and Methods
Study Population
A population-based study, which is part of the Breast Oncology
Galician Network (BREOGAN) Study, was conducted in the city
of Vigo, Spain within a geographically defined health region that
covers aproximately 437,000 inhabitants. The study involved 510
women with operable invasive breast cancer diagnosed and
treated between 1997 and 2010 at the Clinical University Hospital
of Vigo (Vigo, Spain). Ethics approval for this study was obtained
from the Galician Ethics and Research Committee (CEIC, Comite´
E´tico de Investigacio´n Clı´nica de Galicia) associated with the
Complejo Hospitalario Universitario de Vigo from where all
participants were recruited. Written informed consent was
obtained for this study, which was conducted according to the
Spanish law including adherence to the Helsinki Principles of
1975, as revised in 1983.
Data Collection
Risk factor information was collected through a risk factor
questionnaire adapted from the Ella Binational Breast Cancer
Study [15]. Clinical and histopathological information was
abstracted from computerized medical records by trained
physicians. The following variables were recorded: lifetime
breastfeeding (categorized as no breastfeeding, , mean lifetime
breastfeeding duration (7 months), $ mean lifetime breastfeeding
duration (7 months)), age at menarche (categorized as #13 years,
14 years, $15 years), age at first full-term pregnancy (categorized
as #22 years, 23–27 years, $28 years), parity (categorized as
never vs. ever pregnant), age at diagnosis (categorized when
being the main variable of the analysis as ,50 years, $50 years,
otherwise treated as a continous variable), age at menopause
(categorized as ,50 years, $50 years), menopausal status at
diagnosis (categorized as pre, peri and postmenopausal), number
of pregnancies (categorized as none, 1–2, $3), family history
(categorized as none vs. one or more first degree relatives with
breast and/or ovarian cancer), ER, PR and HER2 status
(categorized as positive and negative), grade (categorized as I –
well differenciated -, II – moderately differenciated- and III –
poorly differenciated or undiferenciated), histology type (catego-
rized as invasive ductal carcinoma, invasive lobular carcinoma
and medular carcinoma), and tumor size (categorized as #1 cm,
.1 - ,2 cm, $2 cm). Of the 510 women who participated in
the study, 1 had unknown ER status, 8 had unknown PR status,
9 had unknown ER and PR status and 105 had unknown joint
ER, PR and HER2 status. Thirty eight women had unknown
grade, one had unknown histological type and 21 had unknown
tumor size. Two women had unknown age at menarche and two
(out of 423 parous women) had unknown lifetime breastfeeding.
Clinico-pathological data. Histopathological information
was abstracted from computerized medical records by trained
physicians. Immunohistochemistry (IHC) analyses on paraffin-
embedded material have been previously performed following
standard procedures in Galician hospitals to determine the status
of ER and PR. In every tumor, 4-mm histological sections were cut
and stained with hematoxylin and eosin for histopathological
examination according to the criteria of the World Health
Organization [16]. Histological grading was evaluated using the
Nottingham modification of the Bloom-Richardson system [17].
IHC analysis on paraffin-embedded material was performed using
a universal second antibody kit that used a peroxidase-conjugated
labeleddextran polymer (EnVisionH, Peroxidase/DAB; Dako,
Glostrup, Denmark), with antibodies for ER (clone 6F11, dilution
1:50, water bath; Novocastra, Newcastle-upon- Tyne, UK), PR
(clone PgR 636, dilution 1:50, water bath; Dako, Glostrup,
Denmark). Negative and positive controls were concurrently run
for all antibodies with satisfactory results. Cells were considered
immunopositive when diffuse or dot-like nuclear staining was
observed regardless of the intensity of the staining; only nuclear
immunoreactivity was considered specific. The number of positive
cells was counted by two different observers independently.
Whenever necessary, a consensus was reached using a double-
headed microscope. ER and PR were considered positive when
the percent of immunostained nuclei was $10%.
Immunohistochemistry (IHC) analyses were performed to
determine HER2 status (Dako). No immunostaining (0) or weak
membrane immunostaining (1+) was considered low HER2
expression (HER2-). Strong membrane immunostaining (3+) was
considered HER2 overexpression (HER2+). Moderate membrane
staining (2+) samples were further analyzed using fluorescence in
situ hybridization techniques; they were considered to be HER2+
if the ratio of cerb-B2/centromere 17 copy number was .2.0.
Statistical Analyses
We classified breast tumors according to their expression of ER
(n = 509), PR (n = 502) and joint status of both ER and PR
expression (n = 501). For patients with data available on ER, PR,
and HER2 (n = 405 case patients), we defined four tumor subtypes
(ER+/HER2- or PR+/HER2- [luminal A], ER+/HER2+ or
PR+/HER2+ [luminal B], ER2/PR2/HER2+ [non-luminal],
and ER2/PR2/HER2-[triple negative]), shown in Table 1).
Case-case analysis was conducted. Multivariate logistic regression
was used to estimate odds ratios (ORs), 95% confidence intervals
(CIs), and P values for associations between the different risk
factors and breast cancer subtypes while simultaneously control-
ling for age at diagnosis, age at menarche, age at first full-term
pregnancy (only in analyses restricted to parous women),
menopausal status at diagnosis and family history of first degree
relatives with breast and/or ovarian cancer. Outcome (dependent)
variables were breast cancer subtypes defined by ER, PR, and
HER2 status, and explanatory variable was the risk factor being
studied at the time. P values were calculated using likelihood ratio
tests.
All statistical analyses were performed using the R statistical
software (R_2.13.0). All reported test significance levels (P values)
were two-sided.
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Results
A total of 501 breast cancer patients with known ER and PR
and 405 with known ER, PR, and HER2 were identified. Among
those with known ER and PR status, 85% were ER+/PR+ and
15% were ER-&PR- and among those with data for all three
markers, 71% were ER+/PR+/HER2- (luminal A), 14% were
ER+/PR+/HER2+ (luminal B), 10% were ER2/PR2/HER2-
(TNBC), and 5% were ER2/PR2/HER2+ (non-luminal). The
age of these patients ranged from 28 to 84 years, with a mean of
54.7612.7 years. Detailed characteristics of the study population
are presented in Table 1.
Table 2 shows the associations between breast cancer risk
factors and TNBC in comparison to luminal A breast cancer.
TNBC phenotype was significantly associated with shorter
duration of breastfeeding after adjustment for other breast cancer
risk factors. A lifetime breastfeeding period equal or longer than 7
months was inversely associated with the odds of having a triple-
negative tumor (versus a luminal A tumor) (OR = 0.25, 95%
CI = 0.08– 0.68). Parity was more frequent in case patients with
TNBC compared to luminal A breast cancers (OR = 1.81, 95%
CI = 0.67–6.32). No meaningful associations were found between
other reproductive or menstrual factors and TNBC.
We further examined the joint effect of breastfeeding and parity
and tumor subtype. Table 3 shows the association between the
average lifetime duration of breastfeeding and odds of having
TNBC versus luminal A breast cancer within case groups defined
by parity. Among women with 2 or fewer full-term pregnancies,
breastfeeding for 7 months or longer was inversely associated with
the odds of having a triple-negative tumor versus a luminal A
tumor (OR = 0.09, 95% CI = 0.005–0.54) after adjustment for age
at diagnosis, age at menarche, age at first full-term pregnancy,
menopausal status and family history; however, this finding is
based on only 1 TNBC with number of full-term pregnancies 2 o
lower who breastfed for 7 months or longer. Among women with 3
or more pregnancies, breastfeeding duration of 7 months or longer
was also inversely associated with the odds of having a triple-
negative tumor (versus luminal A tumors) although the association
lacked precison (OR = 0.37, 95% CI = 0.08–1.65). No statistically
significant interaction between breastfeeding and parity and odds
of TNBC vs. luminal A subtype was shown (P = 0.41).
No associations were shown between other breast cancer risk
factors (age at menarche, age at first pregnancy, age at menopause,
and family history) and the different tumor subtypes (Table S1).
Regarding tumor characteristics, high grade (OR = 47.38, 95%
CI = 6.14–365.30, P,0.001) and medullar type breast cancer
(OR = 35.30, 95% CI = 6.84–182.10, P,0.001), were more
frequent in case patients with triple-negative tumors compared
to luminal A tumors (Table S2).
Discussion
In a population-based study of breast cancer patients from
Spain, we observed that the proportion of cases with TNBC versus
luminal A breast cancer was lower in women who breastfed for 7
or more months than in those who did not breastfeed. Also,
compared with luminal A breast cancers, TNBCs were more
common in parous vs. non-parous women. Both a low (2 or fewer
pregnancies) and a high (3–4 pregnancies) number of pregnancies
combined with a long breastfeeding period were associated with
reduced odds of TNBC compared with luminal A breast cancer;
although the association seemed to be slightly more pronounced
among women with a low number of pregnancies we lacked the
statistical power to detect any difference. No other associations
were detected between tumor subtypes and other reproductive/
lifestyle breast cancer risk factors despite the accumulating
evidence favoring distinct reproductive profiles among the
differing tumor subtypes [18,19].
Several case-control and cohort studies have examined the
association between parity and breastfeeding and the risk of
TNBC. Although an inverse association of parity with risk of ER+
breast cancer has been found by many studies, studies of ER–
breast cancer indicate a positive, risk-enhancing association with
parity [18–21]. Studies including ‘‘intrinsic’’ breast cancer
subtypes based on additional molecular markers such as the
basal-like subtype also found high parity to be associated with an
Table 1. Characteristics of the breast cancer patients
included in the study (N = 510).
N (%)
Age at diagnosis 6 SD 54.7612.7 years
Age at menarche 6 SD 13.261.7 years
Age at first full-term pregnancy 6 SD 24.764.6 years
Parity
No 87 (17.1)
Yes 423 (82.9)
Number of pregnancies 6 SD 2.361.0
Breastfeeding
No 144 (34.2)
Yes 277 (65.8)
Lifetime breastfeeding 7.1610.5 months
Grade
I 99 (21.2)
II 233 (49.9)
III 135 (28.9)
Histology type
Ductal Invasive 406 (79.8)
Lobulillar Invasive 50 (9.8)
Medullary 11 (2.2)
Other 42 (8.2)
Tumor size 2.261.3 cm
ER
Positive 422 (82.9)
Negative 87 (17.1)
PR
Positive 348 (69.3)
Negative 154 (30.7)
ER/PR
ER+/PR+ 337 (67.2)
ER+/PR- 78 (15.6)
ER2/PR+ 10 (2.0)
ER2/PR- 76 (15.2)
ER/PR/HER2
ER+/or PR+/HER2- 287 (70.9)
ER+/or PR+/HER2+ 58 (14.3)
ER2/PR2/HER2+ 21 (5.2)
ER2/PR2/HER2- 39 (9.6)
doi:10.1371/journal.pone.0040543.t001
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increased risk [18,19]. In some of these studies, this association was
present only among women who had never breastfed [19,21].
Several studies have reported a lower risk of TNBC in parous
women who have ever breastfed a child [22], or who breastfed for
a cumulative duration of at least 4 [19], 6 [23,24], or 12 months
[25]. Only two case–case analyses have compared the TNBC
subtype with the ER+/PR+ subtype and both found a strong
positive association of parity with TNBC [26] or with ER2/
PR2/HER2+ tumors [27]. Both studies also observed a reduced
odds of TNBC (compared to non-TNBC and to luminal A breast
cancer) associated with breastfeeding [26,27], and, in one, the
positive association of parity with TNBC was present only among
women who had never breastfed [27]. We found some evidence in
support of these findings in our study of Spanish women from
Galicia. We observed reduced odds of TNBC compared to
luminal A breast cancer associated with breastfeeding, and some
Table 2. Associations between breast cancer risk factors/tumor characteristics and triple-negative breast cancer.
Luminal A TNBC
N (%) N (%) OR (95% CI)* Multivariate PLRT
Age at first full-term pregnancy #22 85 (90.4) 9 (9.6) 1.0
23–27 90 (83.3) 18 (16.7) 2.22 (0.93–5.70)
$28 61 (88.4) 8 (11.6) 1.38 (0.48–3.93) 0.190
Age at menarche #13 167 (86.5) 26 (13.5) 1.00
14 64 (88.9) 8 (11.1) 0.82 (0.33–1.85)
$15 52 (91.2) 5 (8.8) 0.65 (0.21–1.68) 0.672
Age at diagnosis ,50 114 (85.1) 20 (14.9) 1.00
$50 169 (89.9) 19 (10.1) 0.58 (0.18–1.81) 0.359
Age at menopause ,50 155 (88.6) 20 (11.4) 1.00
$50 128 (87.1) 19 (12.9) 1.28 (0.63–2.61) 0.488
Menopausal status Pre-menopausal 66 (86.8) 10 (13.2) 1.00
Peri-menopausal 62 (84.9) 11 (15.1) 1.25 (0.48–3.25)
Post-menopausal 155 (89.6) 18 (10.4) 0.99 (0.28–3.44) 0.865
Family History No 226 (87.9) 31 (12.1) 1.00
Yes 57 (87.7) 8 (12.3) 1.09 (0.44–2.43) 0.848
Lifetime duration of breastfeeding No 76 (82.6) 16 (17.4) 1.00
,7 months 69 (83.1) 14 (16.9) 0.91 (0.39–2.06)**
$7 months 89 (94.7) 5 (5.3) 0.25 (0.08–0.68)** 0.012
Parity No 47 (92.2) 4 (7.8) 1.00
Yes 236 (87.19) 35 (12.9) 1.81 (0.67–6.32) 0.258
1–2 164 (86.8) 25 (13.2) 1.80 (0.65–6.38)
$3 72 (87.8) 10 (12.2) 1.84 (0.56–7.23) 0.526
*Adjusted for age at diagnosis, age at menarche, menopausal status and family history except in models with any of these variables as main predictors.
**Further adjusted for age at first full-term pregnancy.
doi:10.1371/journal.pone.0040543.t002
Table 3. Associations between parity and lifetime breastfeeding and luminal A and triple-negative breast cancer.
Luminal A (N=162) TNBC (N=35)
N (%) N (%) OR (95% CI)* Multivariate PLRT
Parity #2
No Breastfeeding 53 (82.8) 11 (17.2) 1.00
Breastfeeding ,7 months 62 (82.7) 13 (17.3) 0.92 (0.36–2.40)
Breastfeeding $7 months 47 (97.9) 1 (2.1) 0.09 (0.005–0.54) 0.009
Parity $3
No Breastfeeding 23 (82.1) 5 (17.9) 1.00
Breastfeeding ,7 months 7 (87.5) 1 (12.5) 0.88 (0.04–8.37)
Breastfeeding $7 months 42 (91.3) 4 (8.7) 0.37 (0.08–1.65) 0.406
*Adjusted for age at diagnosis, age at menarche, age at first full-term pregnancy, menopausal status and family history.
doi:10.1371/journal.pone.0040543.t003
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indication that the combination of a longer breastfeeding duration
and decreased parity may reduce the odds of having a TNBC
compared to a luminal A breast cancer, although this finding was
based on very small numbers (only one TNBC with number of
full-term pregnancies 2 o lower who breastfed for 7 months or
longer).
It is unclear why the inverse association between breastfeeding
and TNBC tends to be more pronounced among Hispanics than
NHWs [26]. In general, Hispanic patients with breast cancer tend
to have ER-negative tumors more frequently than NHW women
[11,12,28,29]. In one study using data from 13 Surveillance,
Epidemiology, and End Results cancer registries over a period
from 1992 through 2004 [30], researchers analyzed age-adjusted
incidence rates and trends from women older than 50 years and
showed an increase in incidence rates of ER and PR-negative
tumors among Hispanic women compared with NHW women
(14.2% in white women compared with 17.3% in Hispanic
women). They reported a relative increase in rates of TNBC in
Hispanic women (from 2001 through 2004) of 26.8%, with an
absolute increase from 34.6 to 43.9 [30]. Our findings that TNBC
was more likely to be of a high grade, and high tumor size at
diagnosis support the hypothesis that the presence or absence of
ER and PR represents distinct biological entities rather than
different stages in the natural history of the disease.
It is possible that genetic susceptibility to breast cancer may
differ among Hispanics and other ethnicities. Major differences in
gene expression between Hispanics and NHW have been detected
[5]. In one such study, researchers [5,31] hypothesized that during
pregnancy, progenitor cells that coexpress GABRP (the gamma-
aminobutyric acid A receptor, GABRP, a type A receptor that is
expressed in reproductive tissues), proliferate within the breast
lobules and then are lost during breastfeeding. These investigators
evaluated 203 newly diagnosed invasive breast cancers and
showed that higher GABRP gene expression was more common
in younger women with a limited history of lactation after
pregnancy study [31]. The same study showed that GABRP gene
expression was higher in Hispanic women compared with white
controls. This investigation suggested that GABRP gene expression
may be associated with high-grade breast cancer in Hispanic
women; although this needs additional study.
The present study was conducted in Galicia, a region located
in the northwest part of Spain, whose history has been defined
by mass emigration to Latin America [13]. In the United States,
Hispanics are a diverse and growing community that represents
12% of the US population [32]. Hispanic ethnicity represents a
culturally and genetically heterogeneous group [33]. Hispanics
are basically tri-hybrid, i.e., their ancestral populations being
European, African, and Native American with the European
contribution usually being the highest, although this varies to a
degree [34]. Because Galicia has been the European state with
one of the highest emigration rates to Latin America, its
population could be, at least partially, a contributor of the
European ancestry to Hispanics in the US. Thus, in a BRCA1
screening study in familial breast cancer carried out in different
centers in Spain, France and the United Kingdom, the missense
mutation 330 A.G was independently identified in six families,
all of them with Spanish/Galician ancestors [35]. This mutation
has been observed in families in diverse geographical locations
(Spain, Caribbean, France, United Kingdom) who would appear
to be of Spanish origin [35]. These studies are consistent with the
possibility that the families studied shared a common ancestry
with BRCA1 330 A.G being a founder mutation of Spanish/
Galician origin. Similarly, the BRCA1 185delAG mutation has
been identified among several apparently non-Jewish families in
Spain [36–40], one Chilean family [41], and in several Mexican
and Hispanic American cohorts [42–44]. The 185delAG families
identified among the Spanish cohorts [36–40] are likely
descendants of the Jewish that remained in Spain, whereas the
carriers reported in the other cohorts are likely descendants of
Spanish Jews who emigrated to the Americas in the late 15th
century and assimilated into the larger Hispanic society [44].
Although our results are mostly in agreement with those of
other studies, limitations of our study should be discussed,
notably its small sample size particularly in subset analyses
stratified by hormonal receptor status ER, PR or HER2. Sample
sizes for the less common subtypes were limited. In addition, the
breastfeeding data were based on self reported information
collected years later. In general, breastfeeding history has been
shown to be accurate and reliable [45,46]. However, other
authors have shown missclassification [47], although it has been
found to be non-differential, i.e., to attenuate the true strength of
the association between breastfeeding and the health event under
study [47]. Thus, even if there was misclassification in the
present study, the true association between breastfeeding and
TNBC would have possibly been stronger than the observed.
Another limitation relates to the fact that since breast cancer
receptor status had been determined from medical records in the
present study, there could be the possibility of potential
heterogeneity in reading stains and scoring of immunohisto-
chemistry; however this limitation would be expected to bias the
study results towards the null. Finally, the case-case study design
has obvious limitations [9]. A study that does not include a
disease-free population does not provide a traditional risk ratio
and may not provide a valid estimate of the association between
a risk factor and disease; thus, the case-case OR estimated in this
study cannot be interpreted as a measure of risk for the specific
subtype. Furthermore, the magnitude of the association is not the
magnitude of risk, but rather an indicator of the general direction
of the correlation between risk factor and subtype. Thus, results
from case-case analyses like ours must be validated in traditional
case-control and cohort studies to asses risk and estimate the
magnitude of the effect.
Our case-case design study can be particularly useful in
assessing the relative correlation of established risk factors and
the different tumor subtypes. We have included in our study
detailed tumor marker information, such as ER, PR and Her-2
receptor status, which is needed to identify etiologic heterogeneity
for established breast cancer risk factors and disease subtypes [9].
In conclusion, this analysis shows that associations between
breast cancer and reproductive factors or breastfeeding vary by
breast cancer tumor subtypes defined by ER, PR, and HER2
status, particularly luminal A and TNBC. These results are in
concordance with emerging evidence that relationships for genetic
susceptibility loci also vary by expression levels of markers in
tumors [48]. Our results support the view that there may be more
than one type of breast cancer from an etiological perspective, and
specifically support the hypothesis that hormone receptor negative
tumors may have a different etiology than hormone receptor
positive tumors. Given the proposed disease heterogeneity
observed in breast cancer, future large epidemiological studies
will be helpful in identifying etiologic heterogeneity for the
established risk factors by disease subtype. Breastfeeding, for
example, may be a potential modifiable factor that may be related
to the development of a specific breast cancer tumor subtype, and
not to all tumor subtypes. Knowledge gained from these studies is
likely to produce important information on specific risk factors by
tumor subtype which would help in risk prediction models and risk
reduction strategies.
Breastfeeding and Breast Cancer
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